<SEC-DOCUMENT>0001140361-23-024688.txt : 20230901
<SEC-HEADER>0001140361-23-024688.hdr.sgml : 20230901
<ACCEPTANCE-DATETIME>20230515160413
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001140361-23-024688
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20230515

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CATALYST BIOSCIENCES, INC.
		CENTRAL INDEX KEY:			0001124105
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				562020050
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		611 GATEWAY BLVD., SUITE 710
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-871-0761

	MAIL ADDRESS:	
		STREET 1:		611 GATEWAY BLVD., SUITE 710
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TARGACEPT INC
		DATE OF NAME CHANGE:	20000919
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 23.3.2.5148
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <u></u><br>
  <div>
    <table id="5e1dc3f8a82c47cf944f53858cf9edc5" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 75%; vertical-align: top;">
            <div style="font-size: 12pt;">May 15, 2023</div>
            <div>&#160;</div>
            <div style="font-size: 12pt;"><a name="DeliveryMethods"></a><u>VIA EDGAR</u></div>
            <br>
          </td>
          <td colspan="1" style="width: 25%; vertical-align: top;"><img src="orrick_logo.jpg" height="67" border="0" width="120"> <br>
          </td>
        </tr>

    </table>
    <div style="font-size: 12pt;"><u> <br>
      </u></div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z741fabab9c4d4d209101bfd628d8a8b4" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 75%; vertical-align: top;">
            <div style="font-size: 12pt;"><a name="Address"></a>United States Securities and Exchange Commission</div>
            <div style="font-size: 12pt;">Division of Corporation Finance, Office of Life Sciences</div>
            <div style="font-size: 12pt;">100 F Street, NE</div>
            <div style="font-size: 12pt;">Washington, DC 20549<br>
              Attn: Jenn Do</div>
            <div style="margin-left: 27pt; font-size: 12pt;">Lynn Dicker</div>
            <div style="margin-left: 27pt; font-size: 12pt;">Daniel Crawford</div>
            <div style="margin-left: 27pt; font-size: 12pt;">Laura Crotty</div>
          </td>
          <td colspan="1" style="width: 25%; vertical-align: top;">
            <div>
              <div style="color: #000000; font-weight: bold;">Orrick, Herrington &amp; Sutcliffe LLP</div>
              <div style="color: #000000;">51 West 52nd Street</div>
              <div style="color: #000000;">New York, NY 10019-6142</div>
              <div style="color: #000000;">+1 212 506 5000</div>
              <div style="color: #000000; font-weight: bold;">orrick.com</div>
              &#160;</div>
            <div>
              <div style="color: #000000; font-weight: bold;">Stephen Thau</div>
              <div style="color: #000000;"><font style="font-weight: bold;">E</font> sthau@orrick.com</div>
              <div style="color: #000000;"><font style="font-weight: bold;">D</font> +1 212 506 5076</div>
              <div style="color: #000000;"><font style="font-weight: bold;">F</font> +1 212 506 5151</div>
            </div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z11cd83c5a9284f52b3ac060186b7f769" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top;"><a name="lblRe"></a><font style="font-size: 12pt; font-weight: bold;">Re:</font></td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-size: 12pt; font-weight: bold;"><a name="RELine"></a>Catalyst Biosciences, Inc.<br>
              Preliminary Proxy Statement on Schedule 14A<br>
              Filed March 30, 2023<br>
              File No. 000-51173</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="font-size: 12pt;"><a name="Salutation"></a>Ladies and Gentlemen:</div>
    <div>&#160;</div>
    <div style="text-indent: 36pt; font-size: 12pt;">On behalf of Catalyst Biosciences, Inc., a Delaware corporation (the &#8220;<u>Company</u>&#8221;), set forth below is the response of the Company to the comments of the staff of the Division of Corporation Finance,
      Office of Life Sciences (the &#8220;<u>Staff</u>&#8221;) of the U.S. Securities and Exchange Commission (the &#8220;<u>Commission</u>&#8221;) contained in the letter dated April 27, 2023 (the &#8220;<u>Comment Letter</u>&#8221;) regarding the Company&#8217;s Preliminary Proxy Statement on
      Schedule&#160;14A (the &#8220;<u>Proxy Statement</u>&#8221;) filed with the Commission on March 30, 2023.</div>
    <div>&#160;</div>
    <div style="text-indent: 36pt; font-size: 12pt;">Concurrently with this response letter, the Company is filing Amendment No. 1 to the Proxy Statement (the &#8220;<u>Amendment</u>&#8221;) via EDGAR.&#160; The Amendment includes revisions made in response to the comments
      of the Staff in the Comment Letter, as well as additional changes to update certain disclosure contained in the Proxy Statement.</div>
    <div>&#160;</div>
    <div style="text-indent: 36pt; font-size: 12pt;">To facilitate your review, we have reproduced the text of the Staff&#8217;s comments in boldfaced print below, followed by the Company&#8217;s response.&#160; We are also providing, on a supplemental basis, a copy of the
      Amendment that has been marked to show changes made to the originally-filed Proxy Statement.</div>
    <div><br>
    </div>
    <div style="font-size: 12pt; font-weight: bold;"><a name="z_Hlk133578313"></a><u>Preliminary Proxy Statement on Schedule 14A</u></div>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;"><u>Letter to Stockholders, page 1</u></div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8e86bc4b6dc643569a9e1ce58fc8fc81" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-size: 12pt; font-weight: bold;">1.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-size: 12pt; font-weight: bold;">Provide prominent disclosure about the legal and operational risks associated with BC being based in and having the majority of its operations in China. Your disclosure should make clear whether
              these risks could result in a material change in the combined company&#8217;s operations and/or the value of its securities or could significantly limit or completely hinder its ability to offer securities to investors and cause the value of its
              securities to significantly decline or be worthless if the business combination is executed. Your disclosure should address how recent statements and regulatory actions by China&#8217;s government, such as those related to the use of variable
              interest entities and data security or anti-monopoly concerns, have or may impact the combined company&#8217;s ability to conduct its business, accept foreign investments, or list on a U.S. or other foreign exchange following the business
              combination.</div>
          </td>
        </tr>

    </table>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="font-size: 12pt;">U.S. Securities and Exchange Commission</div>
    <div style="font-size: 12pt;">May 15, 2023</div>
    <div style="font-size: 12pt;">Page <font class="BRPFPageNumber">2</font></div>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;">Response:</div>
    <div>&#160;</div>
    <div style="font-size: 12pt;">The Company has revised the disclosure on pages 2 and 3 of the Letter to Stockholders of the Amendment to address the Staff&#8217;s comment. In addition, the Company respectfully notes to the Staff that such disclosure is
      prominently displayed elsewhere in the Amendment.<br>
    </div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6549890d1f9e48d081b24eaaaac7181f" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-size: 12pt; font-weight: bold;">2.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-size: 12pt; font-weight: bold;">Please prominently disclose whether the auditor for the PRC-operations portion of the combined company&#8217;s audit would be subject to the determinations announced by the PCAOB on December 16, 2021
              and whether and how the Holding Foreign Companies Accountable Act and related regulations will affect the combined company. In addition, disclose that trading in your securities may be prohibited under the Holding Foreign Companies
              Accountable Act if the PCAOB determines that it cannot inspect or investigate completely your auditor, and that as a result an exchange may determine to delist your securities.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;">Response:</div>
    <div>&#160;</div>
    <div style="font-size: 12pt;">The Company has revised the disclosure on pages 3 and 4 of the Letter to Stockholders of the Amendment to address the Staff&#8217;s comment. In addition, the Company respectfully notes to the Staff that such disclosure is
      prominently displayed elsewhere in the Amendment.<br>
    </div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zdb7236c9aeec4eb19b7be28124c35b9c" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-size: 12pt; font-weight: bold;">3.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-size: 12pt; font-weight: bold;">Provide a description of how cash is transferred through BC&#8217;s organization and disclose your intentions to distribute earnings. Regarding BC, state whether any transfers, dividends, or
              distributions have been made to date between the holding company, its subsidiaries, or to investors, and quantify the amounts where applicable. Provide a cross-reference to the consolidated financial statements.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;">Response:</div>
    <div>&#160;</div>
    <div style="font-size: 12pt;">The Company has revised the disclosure on page 3 of the Letter to Stockholders of the Amendment to address the Staff&#8217;s comment. In addition, the Company respectfully notes to the Staff that such disclosure is prominently
      displayed elsewhere in the Amendment.<br>
    </div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd0c708c13c304c8490a704fc362f176e" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-size: 12pt; font-weight: bold;">4.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-size: 12pt; font-weight: bold;">Where discussing the transaction consideration in the fourth paragraph of the letter to stockholders, please include the valuation expressed as a dollar figure, as you have done on page 3.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;">Response:</div>
    <div>&#160;</div>
    <div style="font-size: 12pt;">The Company has revised the disclosure on pages 1 and 2 of the Letter to Stockholders of the Amendment to address the Staff&#8217;s comment. In addition, the Company respectfully notes to the Staff that such disclosure is
      prominently displayed elsewhere in the Amendment.<br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="font-size: 12pt;">U.S. Securities and Exchange Commission</div>
    <div style="font-size: 12pt;">May 15, 2023</div>
    <div style="font-size: 12pt;">Page <font class="BRPFPageNumber">3</font></div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7a3274916dff4facb972e81aed6e1edf" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-size: 12pt; font-weight: bold;">5.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-size: 12pt; font-weight: bold;">Where discussing the percentages of outstanding shares to be held post-Contribution, please clearly state that the pre-Contribution Catalyst stockholders will go from owning 83.4% of outstanding
              shares, as shown on the organizational chart on page 18, to owning 2.5% and 2.0%, the latter taking into consideration the conversion of Convertible Preferred Stock and the outstanding options of Catalyst and Gyre Options to be granted.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;">Response:</div>
    <div>&#160;</div>
    <div style="font-size: 12pt;">The Company has revised the disclosure on pages 1 and 2 of the Letter to Stockholders of the Amendment and 33 of the Amendment to address the Staff&#8217;s comment.</div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;"><u>Questions and Answers About the Contributions</u><br>
      <u>Who will be the executive officers of the combined company..., page 4</u></div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc51910cb56ff468f97bc370ad98b1c27" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-size: 12pt; font-weight: bold;">6.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-size: 12pt; font-weight: bold;">Please revise the table listing the executive officers of the combined company to indicate from which pre-Contribution entity each individual originates.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;">Response:</div>
    <div>&#160;</div>
    <div style="font-size: 12pt;">The Company has revised the disclosure on pages 4 and 22 of the Amendment to address the Staff&#8217;s comment.</div>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;"><u>Catalyst Biosciences, Inc., page 9</u></div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z39d4105fab3646a88a9c4b6b2a159146" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-size: 12pt; font-weight: bold;">7.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-size: 12pt; font-weight: bold;">We note your statement that a Phase 1 clinical trial of Hydronidone was completed in the U.S.; however, you also state that the company does not anticipate filing an IND for the treatment of NASH
              in the U.S. until late 2023. Please revise your disclosure to clarify whether an IND was filed with the FDA prior to commencement of the referenced Phase 1 clinical trial. In addition, we note your statements that Catalyst plans to commence a
              Phase 2a proof-of-concept clinical study. However, it remains unclear whether the company has engaged with the FDA and has received approval to progress as described. Please explain.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;">Response:</div>
    <div>&#160;</div>
    <div style="font-size: 12pt;">The Company has revised the disclosure on pages 9, 207 and 211 of the Amendment to address the Staff&#8217;s comment.</div>
    <div>&#160;</div>
    <div><a name="z_Hlk133578662"></a><br>
    </div>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;"><u>Summary of the Proxy Statement</u><br>
      <u>The Companies, page 9</u></div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8070f3f2f30146a1922034dc74c8fdf9" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-size: 12pt; font-weight: bold;">8.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-size: 12pt; font-weight: bold;">Disclose each permission or approval that you, your subsidiaries, BC or its subsidiaries are required to obtain from Chinese authorities to operate their businesses and to offer securities. State
              whether you, your subsidiaries, BC or its subsidiaries are covered by permissions requirements from the China Securities Regulatory Commission (CSRC), Cyberspace Administration of China (CAC) or any other governmental agency that is required
              to approve your or BC&#8217;s operations, and state affirmatively whether you and BC have received all requisite permissions or approvals and whether any permissions or approvals have been denied. Please also describe the consequences to you and
              your investors if you, your subsidiaries, BC or its subsidiaries: (i) do not receive or maintain such permissions or approvals, (ii) inadvertently conclude that such permissions or approvals are not required, or (iii) applicable laws,
              regulations, or interpretations change and you are required to obtain such permissions or approvals in the future.</div>
          </td>
        </tr>

    </table>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="font-size: 12pt;">U.S. Securities and Exchange Commission</div>
    <div style="font-size: 12pt;">May 15, 2023</div>
    <div style="font-size: 12pt;">Page <font class="BRPFPageNumber">4</font></div>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;">Response:</div>
    <div>&#160;</div>
    <div style="font-size: 12pt;">The Company has revised the disclosure on pages 26-27 and 241-242 of the Amendment to address the Staff&#8217;s comment.</div>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;"><u>Beijing Continent Pharmaceuticals Co., Ltd, page 10</u></div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd06b15cb0d6b45f69a7f062266dcab96" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-size: 12pt; font-weight: bold;">9.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-size: 12pt; font-weight: bold;">Provide a clear description of how cash is transferred through BC&#8217;s organization. Disclose your intentions to distribute earnings after the business combination. Quantify any cash flows and
              transfers of other assets by type that have occurred between the holding company and BC&#8217;s subsidiaries, and direction of transfer. Quantify any dividends or distributions that a subsidiary have made to the holding company and which entity
              made such transfer, and their tax consequences. Similarly quantify dividends or distributions made to U.S. investors, the source, and their tax consequences. Your disclosure should make clear if no transfers, dividends, or distributions have
              been made to date. Describe any restrictions on foreign exchange and BC&#8217;s ability to transfer cash between entities, across borders, and to U.S. investors. Describe any restrictions and limitations on BC&#8217;s ability to distribute earnings from
              the company, including its subsidiaries, to the parent company and U.S. investors.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;">Response:</div>
    <div>&#160;</div>
    <div style="font-size: 12pt;">The Company has revised the disclosure on pages 12-13 and 264-265 of the Amendment to address the Staff&#8217;s comment.</div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8bc981bc26a0429d99eb0bd5aa9c8ff4" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-size: 12pt; font-weight: bold;">10.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-size: 12pt; font-weight: bold;">We note the following statement on page 10: &#8220;The prevalence of IPF in the PRC increased from 83,002 in 2017 to 131,654 in 2022...&#8221; Please revise this statement to clarify the meaning of the
              numbers cited (i.e., number of cases, number of new patients, etc.).</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <br>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="font-size: 12pt;">U.S. Securities and Exchange Commission</div>
    <div style="font-size: 12pt;">May 15, 2023</div>
    <div style="font-size: 12pt;">Page <font class="BRPFPageNumber">5</font></div>
    <div><br>
    </div>
    <div>
      <div style="font-size: 12pt; font-weight: bold;">Response:</div>
    </div>
    <div><br>
    </div>
    <div style="font-size: 12pt;">The Company has revised the disclosure on pages 10, 72, 228, 229, 232, 233, 235, 236 and 237 of the Amendment to address the Staff&#8217;s comment.</div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4965b50e990d41fc91ba27cb304f4924" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-size: 12pt; font-weight: bold;">11.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-size: 12pt; font-weight: bold;">Please remove the statement on page 10 that the company may &#8220;quickly obtain marketing approvals&#8221; for the treatment of rare diseases and further expand the use of drugs, as the timing of
              regulatory approvals is not within the company&#8217;s control and cannot be predicted.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;">Response:</div>
    <div>&#160;</div>
    <div style="font-size: 12pt;">The Company has revised the disclosure on pages 10 and 277 of the Amendment to address the Staff&#8217;s comment.</div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za46aeda0cab94a89a39d9013758a29a0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-size: 12pt; font-weight: bold;">12.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-size: 12pt; font-weight: bold;">We note the disclosure on page 10 that Hydronidone was granted Breakthrough Therapy designation by the CDE in March 2021. Please define &#8220;CDE&#8221; here and disclose that your Breakthrough Therapy
              designation does not increase the likelihood that Hydronidone will ultimately receive approval.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;">Response:</div>
    <div>&#160;</div>
    <div style="font-size: 12pt;">The Company has revised the disclosure on pages 11, 45 and 225 of the Amendment to address the Staff&#8217;s comment.</div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z999d20211b36457c9c148a9c77459cb6" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-size: 12pt; font-weight: bold;">13.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-size: 12pt; font-weight: bold;">We note disclosure both here and elsewhere throughout the proxy statement stating or inferring that Catalyst and BC&#8217;s product candidates are or may be considered safe and/or effective. For
              example, we note statements that product candidates have &#8220;promising efficacy,&#8221; &#8220;potential efficacy,&#8221; and &#8220;favorable safety.&#8221; Please note that determinations of safety and efficacy are solely within the authority of the FDA and comparable
              regulatory bodies; therefore, please revise your prospectus to remove all references and/or implications of safety and efficacy for unapproved product candidates. You may summarize data and findings of studies and trials conducted without
              drawing conclusions as to these matters.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;">Response:</div>
    <div>&#160;</div>
    <div style="font-size: 12pt;">The Company has revised the disclosure on pages 11, 43, 209, 225, 231, 232, 233, 234, 235, 236 and 239 of the Amendment to address the Staff&#8217;s comment.</div>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;"><u>The Contributions, page 12</u></div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z91a52efd41ac4e6b9f3c694679e9a2fb" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-size: 12pt; font-weight: bold;">14.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-size: 12pt; font-weight: bold;">Disclose that trading in the post-Contribution company&#8217;s securities may be prohibited under the Holding Foreign Companies Accountable Act if the PCAOB determines that it cannot inspect or
              investigate completely your auditor, and that as a result an exchange may determine to delist your securities. Disclose whether the auditor responsible for the combined company&#8217;s PRC-operations would be subject to the determinations announced
              by the PCAOB on December 16, 2021.</div>
          </td>
        </tr>

    </table>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="font-size: 12pt;">U.S. Securities and Exchange Commission</div>
    <div style="font-size: 12pt;">May 15, 2023</div>
    <div style="font-size: 12pt;">Page <font class="BRPFPageNumber">6</font></div>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;">Response:</div>
    <div>&#160;</div>
    <div style="font-size: 12pt;">The Company has revised the disclosure on page 15 of the Amendment to address the Staff&#8217;s comment.</div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z615b0ce8c1584b23a52350d9adef1c1d" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-size: 12pt; font-weight: bold;">15.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-size: 12pt; font-weight: bold;">Please advise us of the exemption you are relying on for the issuance of Catalyst shares pursuant to the Contributions.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;">Response:</div>
    <div>&#160;</div>
    <div style="font-size: 12pt;">The Company respectfully advises the Staff that the Catalyst Common Stock and Catalyst Convertible Preferred Stock issued in the Contributions will be issued in transactions exempt from registration under the Securities
      Act of 1933, as amended, in reliance on Section 4(a)(2) thereof.</div>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;"><u>Organizational Structure, page 18</u></div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3b1276ad768e4ab09acb30ddf92be8dc" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-size: 12pt; font-weight: bold;">16.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-size: 12pt; font-weight: bold;">Please provide the following in this section:</div>
          </td>
        </tr>

    </table>
    <div style="margin-left: 36pt; font-size: 12pt; font-weight: bold;">&#8226; an organizational chart illustrating BC&#8217;s structure before the Contributions;</div>
    <div style="margin-left: 36pt; font-size: 12pt; font-weight: bold;">&#8226; graphically indicate how GNI USA, Inc. relates to the shown entities;</div>
    <div style="margin-left: 36pt; font-size: 12pt; font-weight: bold;">&#8226; explain the difference between BJ Continent Pharmaceuticals Limited and BC in the post-Contribution chart, as your disclosure does not clearly discuss two separate entities for BC;</div>
    <div style="margin-left: 36pt; font-size: 12pt; font-weight: bold;">&#8226; indicate who holds the remaining 30.3% of BC post-Contribution.</div>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;">Response:</div>
    <div>&#160;</div>
    <div style="font-size: 12pt;">The Company has revised the disclosure on page 21 of the Amendment to address the Staff&#8217;s comment.</div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z816103de217243b9bd070b7478991118" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-size: 12pt; font-weight: bold;">17.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-size: 12pt; font-weight: bold;">In reference to footnote 2 to the chart, please revise to define &#8220;Entities&#8221; here rather than referencing the Business Combination Agreement.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;">Response:</div>
    <div>&#160;</div>
    <div style="font-size: 12pt;">The Company has revised the disclosure on page 21 of the Amendment to address the Staff&#8217;s comment.</div>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;"><a name="z_Hlk133787645"></a><u>Interests of Certain Directors, Officers and Affiliates of Catalyst and the Contributors</u><br>
      <u>Interests of Catalyst, page 19</u></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="font-size: 12pt;">U.S. Securities and Exchange Commission</div>
    <div style="font-size: 12pt;">May 15, 2023</div>
    <div style="font-size: 12pt;">Page 7</div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z202b5aa037ec4e39ab660960496d687c" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-size: 12pt; font-weight: bold;">18.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-size: 12pt; font-weight: bold;">Please quantify the dollar value of the grants of awards of fully vested stock options under the 2023 Omnibus Incentive Plan to be granted to Nassim Usman, Seline Miller and Thomas Eastling, as
              discussed on page 19.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;">Response:</div>
    <div>&#160;</div>
    <div style="font-size: 12pt;">The Company respectfully advises that it will provide information regarding quantifying the dollar value of the grants of awards of fully vested stock options under the 2023 Omnibus Incentive Plan to be granted to Nassim
      Usman, Seline Miller and Thomas Eastling in a subsequent amendment.</div>
    <div style="font-size: 12pt;"> <br>
    </div>
    <div style="font-size: 12pt; font-weight: bold;"><u>Risk Factor Summary, page 21</u></div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8fdb5984961342a89a1991b64be31038" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-size: 12pt; font-weight: bold;">19.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-size: 12pt; font-weight: bold;">Please revise here to describe the dilutive effects to existing Catalyst stockholders of the issuance of stock pursuant to the Contributions.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;">Response:</div>
    <div>&#160;</div>
    <div style="font-size: 12pt;">The Company has revised the disclosure on page 24 of the Amendment to address the Staff&#8217;s comment.</div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z29ed07835a4d4defb837267ec4da2b21" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-size: 12pt; font-weight: bold;">20.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-size: 12pt; font-weight: bold;">Please disclose here the risk that the holders of Catalyst Convertible Preferred Stock could be entitled to require Catalyst to redeem, in cash, the shares of common stock underlying its Catalyst
              Convertible Preferred Stock, causing substantial doubt about Catalyst&#8217;s ability to continue as a going concern within one year from the filing of this proxy statement.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;">Response:</div>
    <div>&#160;</div>
    <div style="font-size: 12pt;">The Company has revised the disclosure on page 25 of the Amendment to address the Staff&#8217;s comment.</div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z01e6d34f78dd43a59be817527f727b25" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-size: 12pt; font-weight: bold;">21.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-size: 12pt; font-weight: bold;">In your summary of risk factors, disclose the risks your corporate structure and being based in or having the majority of the company&#8217;s operations in China after the business combination poses to
              investors. In particular, describe the significant regulatory, liquidity, and enforcement risks with cross-references to the more detailed discussion of these risks in the proxy statement. For example, specifically discuss risks arising from
              the legal system in China, including risks and uncertainties regarding the enforcement of laws and that rules and regulations in China can change quickly with little advance notice; and the risk that the Chinese government may intervene or
              influence the combined company&#8217;s operations at any time, or may exert more control over offerings conducted overseas and/or foreign investment in China-based issuers, which could result in a material change in the combined company&#8217;s
              operations and/or the value of its securities. Acknowledge any risks that any actions by the Chinese government to exert more oversight and control over offerings that are conducted overseas and/or foreign investment in China-based issuers
              could significantly limit or completely hinder the combined company&#8217;s ability to offer or continue to offer securities to investors and cause the value of such securities to significantly decline or be worthless.</div>
          </td>
        </tr>

    </table>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="font-size: 12pt;">U.S. Securities and Exchange Commission</div>
    <div style="font-size: 12pt;">May 15, 2023</div>
    <div style="font-size: 12pt;">Page 8</div>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;">Response:</div>
    <div>&#160;</div>
    <div style="font-size: 12pt;">The Company has revised the disclosure on pages 25 and 26 of the Amendment to address the Staff&#8217;s comment.</div>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;"><u>Catalyst stockholders may not realize a benefit from the Contributions commensurate with the ownership dilution . . . ., page 29</u></div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zcc1ce655f3a34ea5988994a4f72c8f6b" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-size: 12pt; font-weight: bold;">22.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-size: 12pt; font-weight: bold;">Please revise here to disclose the amounts and sources of dilution pursuant to the Contributions.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;">Response:</div>
    <div>&#160;</div>
    <div style="font-size: 12pt;">The Company has revised the disclosure on page 33 of the Amendment to address the Staff&#8217;s comment.</div>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;"><u>Risks Related to BC&#8217;s Business Operations in the PRC</u><br>
      <u>The Chinese government may intervene in or influence BC&#8217;s operations at any time, which could result in a change in BC&#8217;s operations., page 87</u></div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za7483aaa02a94720b2f53e458bb51257" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-size: 12pt; font-weight: bold;">23.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-size: 12pt; font-weight: bold;">Please revise here to disclose that the risks discussed under this heading could significantly limit or completely hinder the combined company&#8217;s ability to offer or continue to offer securities
              to investors and cause the value of such securities to significantly decline or be worthless.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;">Response:</div>
    <div>&#160;</div>
    <div style="font-size: 12pt;">The Company has revised the disclosure on page 92 of the Amendment to address the Staff&#8217;s comment.</div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zeaf41969652647a296e6dc3f3e00f979" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-size: 12pt; font-weight: bold;">24.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-size: 12pt; font-weight: bold;">We note your disclosure on page 250 where you discuss the CSRC published Trial Measures. Please disclose how, if at all, the Trial Measures apply to this transaction, whether you and relevant
              parties to this transaction have complied with the obligations under the Trial Measures, and the risks to investors of non-compliance.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;">Response:</div>
    <div>&#160;</div>
    <div style="font-size: 12pt;">The Company has revised the disclosure on page 266 of the Amendment to address the Staff&#8217;s comment.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="font-size: 12pt;">U.S. Securities and Exchange Commission</div>
    <div style="font-size: 12pt;">May 15, 2023</div>
    <div style="font-size: 12pt;">Page 9</div>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;"><u>Risks Related to the Combined Company</u><br>
      <u>The certificate of incorporation and bylaws of the combined company will provide that the Court of Chancery of the State of Delaware . . . ., page 101</u></div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9b8ed955d11043869f08ccb1fe8eb773" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-size: 12pt; font-weight: bold;">25.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-size: 12pt; font-weight: bold;">We note that your forum selection provision of the combined company will identify the Court of Chancery of the State of Delaware as the exclusive forum for certain litigation, including any
              &#8220;derivative action.&#8221; Please disclose whether this provision will apply to actions arising under the Securities Act or Exchange Act. In that regard, we note that Section 27 of the Exchange Act creates exclusive federal jurisdiction over all
              suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder, and Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to
              enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. If the provision applies to Securities Act claims, please also revise your proxy statement to state that there is uncertainty as to whether a
              court would enforce such provision and that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. If this provision does not apply to actions arising under the Securities Act or Exchange
              Act, please also ensure that the exclusive forum provision in the governing documents states this clearly, or tell us how you will inform investors in future filings that the provision does not apply to any actions arising under the
              Securities Act or Exchange Act.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;">Response:</div>
    <div>&#160;</div>
    <div style="font-size: 12pt;">The Company has revised the disclosure on page 106 of the Amendment to address the Staff&#8217;s comment. The Company respectfully confirms to the Staff that the combined company&#8217;s certificate of incorporation and bylaws will
      explicitly state that the forum selection provision does not apply to claims arising under federal securities laws.</div>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;"><u>The Contributions</u><br>
      <u>Catalyst&#8217;s Background of the Contributions, page 114</u></div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z34908a6f829e456ea5db369223f446c2" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-size: 12pt; font-weight: bold;">26.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-size: 12pt; font-weight: bold;">Please revise here to discuss the negotiations between the parties leading to Nassim Usman, Ph.D. remaining as a director and Seline Miller remaining as an executive officer of the combined
              company.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;">Response:</div>
    <div>&#160;</div>
    <div style="font-size: 12pt;">The Company has revised the disclosure on pages 120-121 of the Amendment to address the Staff&#8217;s comment.</div>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;"><u>Opinion of Catalyst&#8217;s Financial Advisor, page 118</u></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="font-size: 12pt;">U.S. Securities and Exchange Commission</div>
    <div style="font-size: 12pt;">May 15, 2023</div>
    <div style="font-size: 12pt;">Page 10</div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3c748408b0234dd1b5c5af6c80271496" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-size: 12pt; font-weight: bold;">27.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-size: 12pt; font-weight: bold;">Please revise here to disclose whether there were any material changes made to the draft documents reviewed by Raymond James disclosed on page 119. If so, disclose those changes.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;">Response:</div>
    <div>&#160;</div>
    <div style="font-size: 12pt;">The Company respectfully acknowledges the Staff&#8217;s comment and advises the Staff that there were no material changes made to the draft documents reviewed by Raymond James. The Company has revised the disclosure on page 125
      of the Amendment to address the Staff&#8217;s comment.<br>
    </div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zcff03b0f3aba4deab467df03bae77968" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-size: 12pt; font-weight: bold;">28.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-size: 12pt; font-weight: bold;">We note you state here that the Raymond James fairness opinion is attached to this proxy statement as Annex C. Annex C appears to be an accounting consent and the full text of the opinion does
              not appear elsewhere in the proxy statement. Please attach the opinion to the proxy statement or otherwise advise.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;">Response:</div>
    <div>&#160;</div>
    <div style="font-size: 12pt;">The Company has revised <u>Annex C</u> attached to the Amendment to address the Staff&#8217;s comment.</div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z17a433ded8e04d50b2f5a2f18acf5494" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-size: 12pt; font-weight: bold;">29.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-size: 12pt; font-weight: bold;">Please revise your disclosure to summarize Raymond James&#8217; discounted cash flow analysis and any other valuation analyses conducted in preparation for rendering the fairness opinion. Please also
              summarize the projections provided to Raymond James and used in reaching the fairness determination and disclose the assumptions and bases relied related thereto.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;">Response:</div>
    <div>&#160;</div>
    <div style="font-size: 12pt;">The Company has revised the disclosure on pages 126-128 of the Amendment to address the Staff&#8217;s comment.</div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0a891689181b45bb8e96d71da2e62b46" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-size: 12pt; font-weight: bold;">30.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-size: 12pt; font-weight: bold;">Please revise to quantify the amount of compensation paid by Catalyst to Raymond James and its affiliates over the past two years.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;">Response:</div>
    <div>&#160;</div>
    <div style="font-size: 12pt;">The Company has revised the disclosure on page 130 of the Amendment to address the Staff&#8217;s comment.</div>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;"><u>The Business Combination Agreement</u><br>
      <u>Conditions to the Completion of the Contributions, page 137</u></div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc4143c23c26b4fadb6adef93c4426c05" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-size: 12pt; font-weight: bold;">31.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-size: 12pt; font-weight: bold;">We note you disclose here that conditions to the completion of the contributions are subject to the satisfaction or waiver by each of the parties. Please revise to state which conditions may be
              waived and revise your Risk Factors if applicable.</div>
          </td>
        </tr>

    </table>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="font-size: 12pt;">U.S. Securities and Exchange Commission</div>
    <div style="font-size: 12pt;">May 15, 2023</div>
    <div style="font-size: 12pt;">Page <font class="BRPFPageNumber">11</font></div>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;">Response:</div>
    <div>&#160;</div>
    <div style="font-size: 12pt;">The Company has revised the disclosure on page 149 of the Amendment to address the Staff&#8217;s comment.</div>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;"><u>Catalyst&#8217;s Business</u><br>
      <u>Summary, page 193</u></div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z46851abfd6084c88aa3d02e2a63d14a0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-size: 12pt; font-weight: bold;">32.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-size: 12pt; font-weight: bold;">We note your statement that Hydronidone performed better than Pirfenidone at comparable dose in the murine NASH model. Please revise your disclosure to provide information regarding any
              head-to-head trials conducted comparing Hydronidone to Pirfenidone directly. If head-to-head trials were not conducted, please remove this statement and any similar comparisons.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;">Response:</div>
    <div>&#160;</div>
    <div style="font-size: 12pt;">The Company has revised the disclosure on page 208 of the Amendment to address the Staff&#8217;s comment.</div>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;"><u>Hydronidone Pre-Clinical Development in NASH, page 198</u></div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z08128c5f6fb44fdab946afb8154a762c" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-size: 12pt; font-weight: bold;">33.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-size: 12pt; font-weight: bold;">We note you plan to use clinical data obtained in the recently completed Phase 2 clinical study of Hydronidone conducted by BC in the PRC. Please revise here to disclose the FDA may not accept
              the data from this clinical study and provide risk factor disclosure that the FDA may require you to conduct additional trials if it does not accept data from BC&#8217;s clinical study or believes that additional data is necessary to supplement
              your clinical study data.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;">Response:</div>
    <div>&#160;</div>
    <div style="font-size: 12pt;">The Company has revised the disclosure on pages 44 and 212 of the Amendment to address the Staff&#8217;s comment.</div>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;"><u>Intellectual Property, page 200</u></div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z979c7f156a484ee1a6e5a0e3ffc1d446" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-size: 12pt; font-weight: bold;">34.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-size: 12pt; font-weight: bold;">Please revise page 201 to disclose all jurisdictions related to the granted patents for your first and second patent families. Please also include the expiration dates or years of each.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;">Response:</div>
    <div>&#160;</div>
    <div style="font-size: 12pt;">The Company has revised the disclosure on page 214 of the Amendment to address the Staff&#8217;s comment.</div>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;"><u>Our Clinical-Stage Product - Hydronidone: A Drug to Reverse Liver Fibrosis Associated with CHB, page 218</u></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="font-size: 12pt;">U.S. Securities and Exchange Commission</div>
    <div style="font-size: 12pt;">May 15, 2023</div>
    <div style="font-size: 12pt;">Page 12</div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8ea8a715c62d464aa83cb11cc59cd92e" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-size: 12pt; font-weight: bold;">35.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-size: 12pt; font-weight: bold;">Please remove your statement that &#8220;Hydronidone is expected to remain the only approved anti-fibrosis drugs for the treatment of CHB in the PRC, for at least a few years after approval, according
              to Frost &amp; Sullivan&#8221; as such statement is premature at this stage of development and implies not only that regulatory approval will be obtained, which is outside of the control of the company and unknown, but also that no competitors will
              develop competing products in the interim.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;">Response:</div>
    <div>&#160;</div>
    <div style="font-size: 12pt;">The Company has revised the disclosure on page 233 of the Amendment to address the Staff&#8217;s comment.</div>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;"><u>Phase 2 Study of Hydronidone for liver fibrosis associated with CHB in the PRC, page 220</u></div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z768ca23f6c304be39be69b2009782f26" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-size: 12pt; font-weight: bold;">36.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-size: 12pt; font-weight: bold;">Please expand BC&#8217;s discussion of the SAEs observed in the Phase 2 study of Hydronidone to describe the SAEs.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;">Response:</div>
    <div>&#160;</div>
    <div style="font-size: 12pt;">The Company has revised the disclosure on page 233 of the Amendment to address the Staff&#8217;s comment.</div>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;"><u>F573: Potential Category 1 New Drug for ALF/ACLF, page 221</u></div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z40f611d55e04478c93990ff8506de0ba" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-size: 12pt; font-weight: bold;">37.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-size: 12pt; font-weight: bold;">Please revise here to summarize the results of the Phase 1 clinical trial for F573. To the extent results are not yet available, state when BC expects to receive them. Regarding the Phase 2
              trial, disclose the trial design, primary and secondary endpoints.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;">Response:</div>
    <div>&#160;</div>
    <div style="font-size: 12pt;">The Company has revised the disclosure on page 235 of the Amendment to address the Staff&#8217;s comment.</div>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;"><u>Our Preclinical-Stage Product Candidates, page 222</u></div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb4a0647ffc6147cb8faadff77cb3c156" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-size: 12pt; font-weight: bold;">38.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-size: 12pt; font-weight: bold;">Please revise your discussion of the F528 and F230 preclinical studies to state whether results you refer to are statistically significant.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;">Response:</div>
    <div>&#160;</div>
    <div style="font-size: 12pt;">The Company has revised the disclosure on page 236-237 of the Amendment to address the Staff&#8217;s comment.</div>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;"><u>Intellectual Property, page 232</u></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="font-size: 12pt;">U.S. Securities and Exchange Commission</div>
    <div style="font-size: 12pt;">May 15, 2023</div>
    <div style="font-size: 12pt;">Page <font class="BRPFPageNumber">13</font></div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z77986fcc545d40aab73ac739dc835bc8" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-size: 12pt; font-weight: bold;">39.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-size: 12pt; font-weight: bold;">Please revise this section to disclose the type of patent protection (e.g., composition of matter, use, or process) and the expected expiration dates, on an individual or patent family basis, for
              all material patents owned by BC.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;">Response:</div>
    <div>&#160;</div>
    <div style="font-size: 12pt;">The Company has revised the disclosure on pages 246-247 of the Amendment to address the Staff&#8217;s comment.</div>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;"><u>BC Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, page 260</u><br>
      <u>Results of Operations, page 264</u></div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6ffefbc9e0444fabbecad65ae4ee1a5c" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-size: 12pt; font-weight: bold;">40.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-size: 12pt; font-weight: bold;">We note from page F-57 that BC&#8217;s trade receivables increased 70% during 2022, as compared to an increase of 21% in total RMB revenues. Please explain the reason(s) for why trade receivables have
              increased at a significantly faster rate than revenues. Quantify how much of the balance has been collected subsequent to December 31, 2022.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;">Response:</div>
    <div>&#160;</div>
    <div style="font-size: 12pt;">The Company respectfully acknowledges the Staff&#8217;s comment and advises the Staff that beginning in February 2022, various regions across China were impacted by COVID-19, resulting in an average increase of approximately 10
      days in collection time from most customers in the affected areas. As a result, the balance of trade receivables increased accordingly. In November and December 2022, COVID-19 spread on a large scale nationwide in China, causing most customers to pay
      their trade receivables that were due by the end of 2022 in January or February 2023. As of December 31, 2022, BC experienced a significant increase in trade receivables amounting to approximately RMB 24 million compared to December 31, 2021. The
      aforementioned trade receivables were fully collected in January and February 2023. As of the end of March 2023, the balance of trade receivables for BC has returned to normal levels, amounting to approximately RMB 89 million. RMB 104.6 million,
      accounting for 96.3% of trade receivables balance as of December 31, 2022, were collected subsequent to December 31, 2022.</div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z634213d99abe4983903085e40c708b9d" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-size: 12pt; font-weight: bold;">41.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-size: 12pt; font-weight: bold;">As disclosed on page 265, we note that BC&#8217;s gross profit margin has approximated 96% in each of the last two years. Please revise the disclosure to explain how BC has maintained such a high level
              of gross profit margin and/or why raw materials and the remaining components of cost of sales, if applicable, is so low. Additionally, describe any known trends or uncertainties that have had or that are reasonably likely to have a material
              favorable or unfavorable impact on revenues or gross profit margins. Refer to Item 303(b)(2)(ii) of Regulation S-K.</div>
          </td>
        </tr>

    </table>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="font-size: 12pt;">U.S. Securities and Exchange Commission</div>
    <div style="font-size: 12pt;">May 15, 2023</div>
    <div style="font-size: 12pt;">Page <font class="BRPFPageNumber">14</font></div>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;">Response:</div>
    <div>&#160;</div>
    <div style="font-size: 12pt;">The Company has revised the disclosure on page 282 of the Amendment to address the Staff&#8217;s comment.</div>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;"><u>BC Financial Statements, page F-32</u></div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2179799ce48c465b81c2571c23bbe101" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-size: 12pt; font-weight: bold;">42.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-size: 12pt; font-weight: bold;">Based on the disclosures discussed on pages 94-95 and 248-249 regarding restrictions on the ability of BC&#8217;s Chinese subsidiaries to remit sufficient foreign currency to offshore entities for such
              offshore entities to be able to pay dividends, make other payments or otherwise satisfy BC&#8217;s foreign-currency-denominated obligations, please address the need for BC to provide the Schedule I per Rule 5-04(c) of Regulation S-X.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;">Response:</div>
    <div>&#160;</div>
    <div style="font-size: 12pt;">The Company respectfully acknowledges the Staff&#8217;s comment and advises the Staff that the Company has considered Rule 5.04(c) of Regulation S-X in relation to limitations on dividends and distributions paid from BC&#8217;s single
      subsidiary in China. BC and BC&#8217;s only subsidiary are both companies incorporated in the PRC. There are no restrictions imposed on renminbi cash dividend payments from BC&#8217;s subsidiary to BC because there are no foreign exchange controls between a
      subsidiary and a parent company both incorporated in the PRC. Therefore, the Company respectfully submits to the Staff that BC&#8217;s situation does not meet the conditions for disclosure of Schedule I required by Rule 5-04(c) of Regulation S-X. The
      Company respectfully advises that it has revised the disclosure on page 265 of the Amendment to clarify that the restrictions to remit sufficient foreign currency apply to BC, not to its subsidiary.</div>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;"><u>11. Intangible Assets, page F-55</u></div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zcfb514b0d0f7461e8f8fc4a64404b049" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-size: 12pt; font-weight: bold;">43.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-size: 12pt; font-weight: bold;">We note product development in progress accounts for most of the intangible assets balance. It is not clear to us why such costs are classified as intangible assets. Please identify the
              transactions that have resulted in these amounts and/or address why these costs, referring to the disclosure on page F-39, are not accounted for as inventories.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="font-size: 12pt; font-weight: bold;">Response:</div>
    <div>&#160;</div>
    <div style="font-size: 12pt;">The Company respectfully advises the Staff that &#8220;product development in progress&#8221; represents certain capitalized development costs incurred for the development of BC&#8217;s product candidates, which were recognized as
      intangible assets in accordance with IAS 38.57. As BC has not received regulatory approval for the commercialization of such product candidates, amounts included in &#8220;product development in progress&#8221; do not represent assets (a) held for sale in the
      ordinary course of business, (b) in the process of production for sales, or (c) in the form of materials or suppliers to be consumed in the production process or in the rendering of services in accordance with IAS 2.6 and are not accounted for as
      inventories.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="font-size: 12pt;">U.S. Securities and Exchange Commission</div>
    <div style="font-size: 12pt;">May 15, 2023</div>
    <div style="font-size: 12pt;">Page <font class="BRPFPageNumber">15</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt; font-size: 12pt;">Please direct any questions concerning this letter to the undersigned at (212)&#160;506-5076 or <font style="color: #0000FF;"><u>sthau@orrick.com.</u></font></div>
    <div>&#160;</div>
    <div style="font-size: 12pt;"><a name="Closing"></a>Very truly yours,</div>
    <div>&#160;</div>
    <div style="font-size: 12pt;"><a name="FromSignature"></a><a name="FirmNameInSignature"></a><u>/s/ Stephen Thau</u></div>
    <div>&#160;</div>
    <div style="font-size: 12pt;">Stephen Thau</div>
    <div>&#160;</div>
    <div style="font-size: 12pt;">ORRICK, HERRINGTON &amp; SUTCLIFF LLP</div>
    <div>&#160;</div>
    <div>
      <div>
        <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z3827c8dc8bdb4420a90eb3b055bbdace" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 18pt; vertical-align: top;"><a name="cc"></a><font style="font-size: 12pt;">cc:</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
              <td style="width: 18pt; vertical-align: top;"><br>
              </td>
              <td style="width: auto; vertical-align: top; font-size: 12pt;">Nassim Usman, Ph.D., President and Chief Executive Officer</td>
            </tr>

        </table>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>orrick_logo.jpg
<TEXT>
begin 644 orrick_logo.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  <%!08%! <&!08(!P<("A$+"@D)
M"A4/$ P1&!4:&1@5&!<;'B<A&QTE'1<8(BXB)2@I*RPK&B O,R\J,B<J*RK_
MVP!# 0<(" H)"A0+"Q0J'!@<*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" *D!+ # 2(  A$! Q$!_\0
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MK9CE2:,/$ZNIZ,IR*ZHSC/X64FF.HHHJQA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !45Q<PVL1DN)%C4=R>M96I^(H;7,5IB:7H6_A7_ !KFI)+O4KC+
M>9/(>@ SCZ#M7-4Q"CI'5DN1L7_BAVRE@FP?\]''/X"L&6:2>0O-(TC'NQS6
MM;>&;V;!F*P+_M')_(5JP>%[./!F:28]\G:/T_QKF=.M5U9-FSD:DCMYIO\
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MG\*ZZ>*:TF6I=SO:*S=-UJWU$!/]5-WC8]?H>]:5=\9*2NC3<****H HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBHKFY2UBWR9))PJJ,LQ] *3=MP'331V\+2SN$1>I-<U=ZE>ZU
M(UOIL3K#T8CC=]3V'M6B=,GU.83:JVR,<I;(>GU/K6I%%'!&(X45$'15&*QD
MI5--E^).K,*R\+1IAKZ3S&_N)P/SZG]*W(;>&VCV01K&OHHQ4=[J%IIML;B_
MN([>(=7D; ^GN:X+6_BU:P;HM"M3<MT\Z?*I^"]3^.*5Z5%!I$]%K'U+Q;H6
MD$K?:G CCK&C;V'_  %<D5XGJ_B_7-:W"]OY/*;_ )8Q'8F/3 Z_CFL,USRQ
MG\J)<^QZ]?\ Q@TJ'(T^QN;HCNY$:G^9_2N>O/C!K$I(L[*TMU_VPSM^>0/T
MKS\TAKG>)JOJ3S,ZJ;XF^*I6.W45B'HEO'_52:J-\0O%1ZZQ+^"(/Z5SQIAJ
M/:3[L+LZ+_A8/BG_ *#,W_?*_P"%*OQ&\61_=UB3_@449_FM<V:::?M)]V%V
M=I;?%KQ1 1YLUM<X[2P 9_[YQ6Y9?&R9<#4M'C?U:"8KC\"#_.O+#2&K5:HN
MH[L]ZT[XL^&+XA;B:>Q<\8N(N,_5<C\\5UMCJ5CJ</FZ=>074?\ >AD#@?E7
MRJ:?;W5Q9S+-:3R02KT>)RK#\16\<5+[2*YCZPJG=Z39WN3-" Y_C7AJ\/T3
MXM^(=+*I?,FIP#J)QA\>SC^H->E^'OB?X>UXI%).=/NFX\JZ( )]GZ']#[5T
MQJTZFC'=,EOO#-Q!E[1O/3^[T8?XUB,K(Q5U*L."",$5Z/UZ54OM,M=03$\?
MS=G7AA^-8U,*GK 3CV."HK3U+0[C3\NO[V'^^HZ?45F5PRBXNS(V"BBBI$%%
M%% "@E2"IP1R".U=%I/B,C;!J)R.BS>GU_QKG**TA4E!W0T['HX(905((/((
M[TM<;I&MR6#"*;+VY/3NGN/\*Z^*5)HEDB8.C#(8=Z]2G5C46AJG<?1116HP
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[_C^5=O!;PVL*PVT20Q*,*D:A5'T J2BO0C",%:*-$D@HHHJQA1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBH+Z]@TZQFN[M]D,*E
MF;_/>ANVK S/%/B.#PWI1G?#W$F5@BS]YO4^P[__ %Z\/O;RXU"\ENKR1I9I
M6W,Q[U?\0ZY<>(-7DO+C*K]V*//$:=A_C[UDFO#Q%=U9:;(YY2NQIIIIQIIK
MF)&FFFG&FFF AIAIYJWI.D7>N:G'8Z?'OED/)/1!W8GL!5)-NR&-TC1[W7-1
M2RTZ(R2OU/\ "@[L3V%>W>$_!ECX7M@R@3WSC]Y<L.?HOH/YU:\,^&;/PSI@
MMK10\K &:<CYI&_H/05LUZ]##JFKRW-HQL%%%%=984444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !7,^*M'WH=0ME^91^^4=Q_>KIJ0@,I##((P0>
M]14@IQY6)JYY9FC-:.O:8=+U$JH/D2?-&?;T_"LO->-*+B[,R'YHS3,T9J1#
M\T9IF:,T 7]+U%]-U!+A.5'#K_>7N*]&BE2:%)8F#(X#*1W%>59KK_!^I^9$
M]A*W*?/%GT[C^OXUV86I9\CZEQ?0ZBBBBO2- HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ KRWXD^(S=WHT>U?]S;G,Y'\3^GX?S^E=WXH
MUI=!T&>[R/.(V0@]W/3\NOX5X7([2R,\C%G8DLQ/))[UYV-K67LUU,JDNA'3
M33J::\HR&FFFG&FFF TTTTXTTTP'0P2W-Q'!;HTDLC!411RQ/05[IX-\*0^&
M-*VMM>]F -Q*/7^Z/8?KUKF?A?X6$<7]O7T?SOE;56'0="_X]!^/K7I->KA:
M/*N>6YM"/4****[S0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** ,W7M,&IZ6\:C]\GSQ'W]/QZ5YN20<'@BO6J\_\6Z=]AU8S(,17
M/SCV;^(?U_&N'%T].=$274Q,T9IF:,UYYF/S1FF9HS0 _-6+&\>QOHKF/[T;
M9QZCN/RJIFC-";3N@/6X)DN+>.:(Y210RGV-/KFO!>H>?I[V;GYX#E?]T_\
MU\_F*Z6O;ISYXJ1LG=!1115C"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ"BBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5XKJ*^7JET@_AF<?^/&O:J\6UD_\ $]O_ /KYD_\ 0C7!C=D1
M,JYHS3,T9KS3,?FC-,S1F@!^:EMI-EU$_P#=<']:KYI5/S#ZT >ZT445]";A
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!F>)%W^%]3 _Y]9#^2DUX2:]
M_P!3B\_2+R+_ )Z0.OYJ17@!KR<>O>BS&IN----.--->:9#:::=335#&FFFG
M&FFF!]%Z6_F:/9O_ 'H$/_CHJU63X5F\_P (Z6^<_P"BQJ?J!C^E:U?1Q=XI
MG2M@HHHJAA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !7A^HR^9JETX/WIG/\ X\:]LN)A;VLLS=(T+G\!FO!RY9B3
MR2<FO/QK^%$3'YHS3,T9KS3,?FC-,S1F@!^:DMQYEU$@_B<#]:@S5[0X_/\
M$%A$!]ZXCS]-PS51U:0'MU%%%?0&X4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 !&1@]*^?+R#[-?3P'K%(R?D<5]!UXEXSM?LGC#4$Q@/)Y@]]P#?UKS
M<?'W8R,JFQ@FFFG&FFO),1M--.IIJAC3333C333 ]K^&]S]H\$VRYR8'>,_]
M]$_R85U5><_".\W6>HV1/*2+,H]<C!_]!%>C5[V'ES4HLZ([!1116Y04444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!C
M>+KO['X3OY,X+Q^6/^!';_6O&,UZ-\3K_P NPL[!3S+(96QZ*,#]3^E>;YKR
M,9*]2W8REN.S1FFYHS7(2.S1FFYHS0 [-=#X&M_M/BZU[K$&D/X*<?J17.9K
MO/AA9[KN^O2/N(L2GZG)_P#01^=;4(\U5(:W/1J***]PV"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "H+VU2^L)[2;[D\;1M]",5/
M12:NK ?/-U;R6EW+;3#$D+E&'H0<&H#79_$G2?L7B!;V-<17J[C[..#_ $/X
MFN,-?.5(.G-Q.5JSL-IIIU--2 TTTTXTTTP&FO7OA;K(O?#\FG2-^]LG^7/=
M&Y'Y'(_*O(36YX-US^P/$UO<R-BWD_=3_P"X>_X'!_"NC#U/9U$RHNS/>Z*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M :"QSI]J>"(V_>./=NWT'ZUQO7K17!4Q52>BT1#DV&<T445R$A1110 4444
M%6],TR\UB_2STZ%IIGZ = /4GL/>M7PSX-U+Q-,# GD6@.'N9!\H]A_>/M^>
M*]GT#PYI_ARQ^SZ?%\S?ZR9N7D/N?Z=*ZZ&&E4U>B*4;F?X0\&6OABUWMMGO
MY%Q+/CI_LKZ#^?Z5TM%%>Q&*@N6)KL%%%%4 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4L< 52P5-;W'RH\[L?A#91D'4=2GG_V84$8_,Y_I74Z;X,\/Z5@VVFPM(/\
MEI,/,;/K\V<?A1J'C7PWI8/VS6K0$=4CD\QA_P !7)KDM4^->BVP*Z79W-\_
M9FQ$A_$Y/Z5HHT*?8-$>D].E4-5UO3-$M_.U:^AM4[>8V"WT'4_A7AVL_%SQ
M)J8:.TDBTV(]K=?G(_WCD_EBN11-1US4E1?M%_>3' R3([G^=3+$K:*#F/5?
M$7QJB3?!X9M/,/3[5<C"_4)U/XX^E<_H'A3Q%\2-074]>NYUL >;B3^(=UB7
MH/KC ]^E=)X-^$$5L8[[Q5MFE'S+9*<HO^^?XOH./K7JB(L<:I&H1%&%51@
M>@%.-.=36I]P6;W*6CZ-8:#IL=CI=NL$"=AU8^I/<^]7J**ZMMB@HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HJKJFHPZ1I-WJ-UN,%I"\TFP9;:H).!ZX%>>_\+[\(?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 8/CK_DGOB#_ +!MQ_Z+:OCVOL+QU_R3WQ!_
MV#;C_P!%M7Q[6L-C.844459!ZM^SW_R/E_\ ]@Q__1L=?15?.O[/?_(^7_\
MV#'_ /1L=?158RW-8[!1114E!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 8/CK_ ))[X@_[!MQ_
MZ+:OCVOL+QU_R3WQ!_V#;C_T6U?'M:PV,YA1115D'JW[/?\ R/M__P!@Q_\
MT;'7T57SI^SW_P C[?\ _8,?_P!&Q5]%UC+<UCL%%%%24%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!@^.O^2>^(/\ L&W'_HMJ^/:^PO'7_)/?$'_8-N/_ $6U?'M:PV,YA111
M5D'JO[/?_(_7_P#V#'_]&Q5]%U\Z?L]_\C]??]@Q_P#T;%7T76,MS6.P4445
M)04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% &#XZ_P"2>^(/^P;<?^BVKX]K["\=?\D]\0?]@VX_
M]%M7Q[6L-C.844459!ZK^SW_ ,C]??\ 8,?_ -&Q5]%U\Z?L]_\ (_7W_8,?
M_P!&Q5]%UC+<UCL%%%%24%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!@^.O^2>^(/\ L&W'_HMJ
M^/:^PO'7_)/?$'_8-N/_ $6U?'M:PV,YA1115D'JO[/G_(_WW_8,?_T;%7T7
M7SI^SY_R/]]_V#)/_1L5?1=8RW-8[!1114E!1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8/CK_D
MGOB#_L&W'_HMJ^/:^PO'7_)/?$'_ &#;C_T6U?'M:PV,YA1115D'JG[/G_(_
MWW_8,D_]&Q5]&5\Y_L^?\E OO^P7)_Z-BKZ,K&6YK'8****DH**** "BBB@
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MB@ HKS'X^.R?#N HQ4_VA'R#C^!Z^<?/F_YZO_WT:M1NB7*S/MRBOB/SYO\
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M)!_RSMB9CGT^0''XUR%_^T'X>@)73],U"Z([N$C4_J3^E?/%%5R(GF9[7/\
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M]\0?]@VX_P#1;5\>U]A>.O\ DGOB#_L&W'_HMJ^/:UAL9S"BBBK(/5/V?/\
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L3Q9XKT[P=H4FI:H_
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M/^PC'_Z!)7S=7TA\?_\ DG=O_P!A&/\ ] DKYOK6&QE+<****LD]!\(?$?\
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M//9'5+A>LMZ=RY_W!\N/J#7<V]M!:0K#:PQPQ+T2- JC\!4E%1=LNU@HHHI
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M?8^GV-OI>FV]C9)Y=O;1+%&OHJC J)O2Q<5U+%%%%9&@4444 %%%% !1110
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MCW(;_P =KQRNM^%VI?V7\3=%F+862?[.WOY@*?S842U0+<^LZ***P-@HHHH
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M@C^/49"?^^(Q_2IEL5'<]0HHHK$U"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /+OC]8"Y\ V]V!\]I>H2?165E/Z[:^<*^JOC#")_A3K
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M=CT/5H_YD?C[5[E6,KW-H[!1114C"BBB@ HHHH **** "BBB@ HHHH ****
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M_P \HE3\ABIJYS<**** /+OV@/\ DGMK_P!A*/\ ]%R5\X5]'_M ?\D\M?\
ML)1_^BY*^<*UAL92W"BBBK)/H7]GG_D4-4_Z_O\ VFM>MUY)^SS_ ,B=J?\
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MY$W4O^P@?_1:5ZU7DW[/7_(EZE_V$#_Z+2O6:QEN;1V"BBBI&%%%% !1110
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M,****L@]+^ W_)2?^W*7^:U]*U\T_ ?_ )*4/^O*7^:U]+5E/<UCL(2%4EB
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M_")ZI+\RY>P=CU'5H_YD?C[5[;7Q+:74]C>0W5I*T,\#B2.13@JP.017UGX
M\8P>-?"T-^FU+J/]U=Q#^"0#D_0]1]<=JRDNII%]#IZ***@L**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \V^.>AG5
M/A^;V)-TVFS+-D==A^5A^H/_  &OFBOMB_LH=2TVYL;M=\%S$T4B^JL,']#7
MQMKFD7&@Z]>Z5>#]]:3-&QQ][!X8>Q&#^-:P?0SDNI0HHHJR#ZU^&OB8>*O
MMC>/)ONH5^SW7//F*,9/U&&_&NKKYG^"_C$>'/%G]G7LFVPU0K&Q8\1R_P #
M?CG:?J/2OIBL9*S-HNZ"BBBI&%%%% !1110 4444 %%%% !1110 4444 %%%
M% !63XIUZ'PSX7O]7N,$6T19%/\ &YX5?Q8@5K5\_P#QX\9"_P!4B\,V,F8+
M)O,NRIX:4CA?^ @_F?:FE=B;LCR2YN);NZEN;ES)-,YDD<]68G)/YU%116YB
M%?0'[/FAFVT'4=:E3#7DPAB)_N)U(^K-C_@->"6UM+>7<-M;(9)IG6.-!U9B
M< ?G7V-X8T2+PYX7T_2(<$6L(1F'\3=6;\6)/XU$WH7%:FK11161H%%%% 'E
MW[0'_)/+;_L(Q_\ HN2OG"OI#X__ /)/+;_L(Q_^BY*^;ZUAL92W"BBBK)/H
MC]GK_D2=1_["+?\ HM*]8KRC]GK_ )$?4/\ L(M_Z+CKU>L9;FT=@HHHJ1A1
M110 4444 %%%% !1110 4444 > ?M$?\C%H__7H__H=>/5[#^T1_R,>C_P#7
MHW_H=>/5M'8REN%%%%42?6WPQ_Y)CH7_ %[#^9KJJY7X8_\ ),="_P"O4?S-
M=56#W-EL%%%%(84444 %%%% !1110 4444 %%%% 'RG\7O\ DJ^M?[\7_HI*
MXNNT^+O_ "5;6O\ ?C_]%)7%UNMC%[A5K2_^0O9_]=T_]"%5:M:7_P A>S_Z
M[I_Z$*8C[6HHHKG-PHHHH **** /E;XO:&=#^)&H;4VPWI%W%[[_ +W_ (^&
MKB*^B/CYX;.H>%[;6[=,S:;)MEP.L3D#/X-M_,U\[UM%W1E)685VWPF\3CPS
MX^M7N'V6EZ/LLY)X 8C:WX,!SZ9KB:*IZB/N"BN&^$_C(>+?!\:W4F[4; "&
MY!/+C'RO^('Y@UW-8/0VW"BBBD 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 8/CK_DGOB#_L&W'_ *+:OCVOL+QU_P D]\0?]@VX
M_P#1;5\>UK#8SF%%%%60>D_ C_DI2_\ 7G+_ .RU[]XK\2VGA/PW=:M?'*Q+
MB./.#*Y^ZH^I_(9/:O /@20OQ*4DX'V.7)/X57^+7CL^+_$AMK&3.E6#%(,'
MB5_XI/Z#V^IK-J\BT[(XS6-6N]=UBYU/49/,N;F0N[=O8#T & !Z"J5%%:$!
M5G3M/NM6U*WL+")IKFXD$<:+W)_SUJM7T%\$/ 7]F:>/$^J18N[M,6:,.8XC
M_']6[>WUI-V0TKL[[P3X2M?!GAB#3+;:\OW[F8#_ %LAZGZ=A[ 5T%%%8&Q!
M>V=OJ-C-9WL2S6\Z&.2-NC*1@BODOQYX/N/!?BB;3I=SVS_O+68_\M(R>/Q'
M0^X]Q7UW7(_$CP3%XU\+R6T85=0MLRV<AXPV.5)]&Z?D>U5%V9,E<^3:*DGA
MEMKB2"XC:.6)BCHPP58'!!'K4=;&05UWPW\:R>"O%,=S(S'3[C$5Y&.<IGA@
M/5>OYCO7(T4;C/MV&:.YMXY[=UDBD4.CJ<AE(R"#Z4^O%O@7X[\^#_A%-3E_
M>Q O8.Q^\O5H_P .H]L^@KVFL&K,U3N@HHHI#"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *\*^/WA/R[BU\46B?+)BWN\#
MHP^XQ^H^7\%]:]UJCK6D6NO:)=Z7J";[>ZC,;CN/0CW!P1[BFG9B:NCXMHK3
M\1Z#>>&?$%WI.H+B:W? ;'#K_"P]B,&LRMS$*^F_A%X_7Q7H(T[4)<ZM8( ^
MX\SQ]!)]>@/O@]Z^9*OZ+K-]X?UBWU/2YC#<V[;E;L?4$=P1P14R5T-.Q]HT
M5S'@7QSI_CC1!=6I$5W$ +JU)^:)O7W4]C_6NGK$V"BBB@ HHHH **** "BB
MB@ HHHH **** "BBL3Q9XLTWP=H<FI:I)_LPPJ?GF?LJ_P"/:@#)^)7CJ'P3
MX;:2)E;4[D%+2(\\]W(]%_4X%?*<TTES<23W#M)+(Q=W8Y+,3DDGUK5\4>)M
M0\6Z]-JFJ/F23A(Q]V)!T1?8?KR>]8];15D92=PHHJUING76K:G;Z?81&6YN
M9!'&@[D_T]ZHD]*^!7A,ZMXG?7;J/-IIG^KR.&F(X_[Y'/U*U]&5B>$/#5MX
M2\+VFD6N&,2YED _UDAY9OSZ>V!6W6$G=FR5D%%%%(84444 >7_'_P#Y)W;?
M]A&/_P! DKYOKZ0^/_\ R3NW_P"PC'_Z!)7S?6L-C*6X44459)]$_L]_\B-J
M'_82;_T5'7J]>4_L]_\ (BZA_P!A)_\ T5'7JU8RW-H[!1114C"BBB@ HHHH
M **** "BBB@ HHHH \ _:(_Y&/1_^O1O_0Z\>KV']HC_ )&32/\ KT;_ -#K
MQZMH[&4MPHHHJB3ZV^&7_),M"_Z]1_,UU5<M\,O^29:%_P!>H_F:ZFL'N;+8
M****0PHHHH **** "BBB@ HHHH **** /E/XN_\ )5M:_P!^/_T4E<77:?%W
M_DJVM?[\?_HI*XNMUL8O<*M:7_R%[/\ Z[I_Z$*JU:TO_D+V?_7=/_0A3$?:
MU%%%<YN%%%% !1110!7U"PM]4TVYL+U/,M[F)HI%]588-?'?B70;GPSXDO=(
MO!^\MI"H;&-Z]58?4$&OLRO)OCEX).KZ,OB+3XMUWIZ;;A5',D/7/_ 3D_0G
MTJXNS)DKH^>****U,CHO _BZY\%^)X-3@#20_P"KN80?];&>H^HZCW%?6FF:
ME::QI=OJ&G3+-;7"!XW7N#_(]B.QKXIKT7X5_$M_!]__ &=JKN^C7#9;N;=S
M_&!Z>H_$<\&)1N7%V/INBH[>XAN[:.XM94FAE4.DB-E64]"#W%25D:!1110
M4444 %%%% !1110 4444 %%%% !117DGB[XZ6FB^(8['0K6/4K>%\7<Y<@-Z
MK&1W']XY';WII-B;L>MT5C>&/%>D^+M*6^T6X$B])(FXDB;T9>W\CVK9I#"B
MBB@ HHHH P?'7_)/?$'_ &#;C_T6U?'M?87CK_DGOB#_ +!MQ_Z+:OCVM8;&
M<PHHHJR"WI^J7>EM<-82F%[B!K=V7KL;&X#TR!C\:J444 %%%7='TF[UW6+;
M3--C\VYN9 B+V'J3Z #))]!0!UWPI\"-XQ\2"6]C/]E6)#W)/20_PQ_CW]L^
MHKZD5510J *JC  & !6-X2\,VGA'PW;:38C(C&Z67&#+(?O,?K^@ ':MJL9.
M[-DK(****D84444 >%_'/P'Y4G_"6:7%\CD)?HHZ'HLGX\ ^^#W->)U]MW=K
M!?6<UK=Q+-!.ACDC89#*1@@U\F?$#P;/X*\42V+;GM)/WMI,?XXR>A]QT/Y]
MQ6L7T,Y+J<O1115D$]E>W&G7T%Y92M#<6\@DCD7JK Y!KZU\">+K?QIX6@U*
M+:EPO[NZA'_+.0#G\#U'L:^0Z[+X9>-G\%^*4EF9CIMUB*\0<X7LX'JN<_3(
M[U,E=%1=F?5U%-BD2:))875XW4,K*<A@>A!IU8FH4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YQ\7_A__ ,)7H@U+
M3(LZM8(2JJ.9X^I3ZCDC\1WKYG(()!&".H-?;]>&?&3X8E'G\4>'X<HV7O[9
M!]T]Y5'I_>'X^N-(RZ$274\2HHHK0S-+0=?U'PUJ\6I:/<-!<1GJ.5<=U8=P
M?2OICP#\3=+\;6RP,5L]65?WEHS?>]60_P 0]NH_4_*M/AFEMYTFMY'BEC8,
MCHQ5E(Z$$=#4N-RD['V[17@O@GX[SVBQV/C&-KF(85;Z)?WBC_;7^+ZCGV->
MV:1K>FZ]8K>:/>PWD!_CB;.#Z$=0?8\UDTT:)IEZBBBD,**** "BBB@ HHHH
M **KWU_::99O=ZC<Q6MO&,M+,X51^)KQWQK\>(HUDLO!D?F/T-_,GRK_ +B'
MK]6_(TTFQ-I'H/C;Q_I'@C3_ #+Z3SKV1<P6<;?/)[G^ZON?PSTKYC\5>*]4
M\8:R^H:O-N;I%$O"0K_=4?UZFLR^OKK4KV6\U"XDN;B5MSRRL69C]:KUJHV,
MW*X44451(5]!_!/X?'2;(>)=7AVWMTF+2-QS%$?XOJW\OK7)?"'X9-X@NH]>
MUV$C2X&S!$X_X^G!_P#0 ?S/'K7T5TZ5G*70TBNH4445F6%%%% !1110!Y?\
M?_\ DG=O_P!A&/\ ] DKYOKZ0^/_ /R3NW_[",?_ *!)7S?6L-C*6X44459)
M]%?L]_\ (B7_ /V$G_\ 14=>K5Y3^SW_ ,B'?_\ 82?_ -%1UZM6,MS:.P44
M45(PHHHH **** "BBB@ HHHH **** /G_P#:(_Y&32/^O1O_ $.O'Z]@_:(_
MY&32/^O1O_0Z\?K:.QE+<****HD^M_AG_P DST+_ *]5_F:ZFN6^&G_),]"_
MZ]%_K74U@]S9;!1112&%%%% !1110 4444 %%%% !1110!\I?%W_ )*MK?\
MOQ_^BDKC*[/XN?\ )5M;_P"ND?\ Z*2N,K=;&+W"K6E_\A>S_P"NZ?\ H0JK
M5K2_^0O9_P#7=/\ T(4Q'VM1117.;A1110 4444 %(RAU*N RD8((R"*6B@#
MY?\ BOX ?P?KQN["(_V/>L6@('$+]3&?YCV^AKS^OM#7-$L?$6BW&EZI$);:
MX7:P[J>S ]B#R#7REXV\%ZAX)UQK*^!D@?+6UR!A9D_H1W';Z8-:QE<RDK'.
M44459)Z#\./BI>^#)EL;_?>:,[?-%G+P9ZLG]5Z'VKZ1T?6M.U_38[_1[N.Z
MMI.CH>A]".H/L>:^+:VO#/BW6?".H?:]$NVA+8\R)OFCE'HR]_KU'8U$HW*4
MK'V-17FO@[XU:%X@6.VUEETB_/&)6_<N?]E^WT;'U->DJP90RD%2,@@]:S::
M-+W%HHHI#"BBB@ HHHH **** "H[BYAM+:2XNI4AAB4L\DC!54#J23TKC_%W
MQ3\.>$D>*2X%_?KP+2U8,0?]INB_CS[&OG_QG\1M<\:SE;Z7[/8JV8[*$D(/
M0M_>/N?P JE%LER2.P^)OQA?6TET;PM(\.GG*SW?W7N!_=7NJ_J?8=?(Z**U
M2L9MW-/0/$6I^&-5CU#1KIK>=>#CE9%_NL.XKZ6^'_Q-TSQM;"!]MGJR+F2U
M9N']60]Q[=1^I^5JU?#6F:MJWB*TM?#PD^WF0-$\;%3'C^,L.@'7-*23&FT?
M9=%5=,ANK?2[:'4;D75W'$JS3A HD<#EL#IDU:K$U"BBB@#!\=?\D]\0?]@V
MX_\ 1;5\>U]A>.O^2>^(/^P;<?\ HMJ^/:UAL9S"BBBK("BBB@ KZ,^"G@+^
MPM'_ +?U.+&H7Z?N58<PPGD?BW7Z8]Z\W^$/@/\ X2SQ#]NU"+=I6GL&D##B
M:3JL?N.Y]N.]?3G3I6<WT+BNH4445F:!1110 4444 %<I\1?!</C7PM): *M
M]!F6SE/\+X^Z3Z-T/X'M75T4; ?$=Q;S6EU+;W,;130N4DC88*L#@@_C4=>W
M_'3P'@_\)9I<7!PE^BC\%D_D#^!]:\0K=.Z,6K,****8CWSX&>._MEG_ ,(M
MJ<N9[=2UB['[\8ZQ_5>H]L^E>R5\4:??W.EZC;WUA*T-S;R"2-U[$&OK?P3X
MLMO&7A>WU2WVI*1LN(0?]5*.H^G<>Q%925M32+Z'04445!84444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !00""",@]0:** /
M!/BG\(7LFFU[PI 6MCE[FQC',7JR#NOJ.W;CIXU7W!7DWQ%^#%OKC2ZKX66.
MUU%B6EM2=L4Y]1_=;]#[<FM(RZ,B4>Q\\459U#3[S2KZ6RU*VDMKF([7BE7!
M!JM6AF%7-,U?4=%O!=:3>SV<X_CA<J3['U'L:IT4 >M^'_C_ *U9*L7B"QAU
M.,<&6,^3)]3@%3^0KT/2?C=X.U)5%S=3Z=(?X;J$XS_O+D?GBOF&BI<45S,^
MRK'Q5X?U( V&MZ?<9[1W*$_EG-::RQL,K(I'J&%?$5%3R#YS[;:ZMT^_/&OU
M<"J5WXDT2P4M>ZQ86X'_ #UN47^9KXQHHY YSZDU7XS>"],4A-1>^D'\%I"6
MS_P(X7]:\_U_]H2_G5XO#FEQVBG@3W3>8_U"C !^I->-T52BA<S-/6_$>L>(
M[K[1K>H3WCC[HD;Y4_W5'"_@*S***HD***D@@FNKA(+:)YII&"I'&I9F)[ #
MJ: (Z]0^%_PGG\32Q:OK\;P:0IW1QGY6NOIZ)[]^WJ.D^'?P2$+1:KXSC5G&
M&BT[.0/0R'O_ +OY^E>UJJHH5 %51@ #  K.4NQ:CW&PPQ6\"0V\:Q11J%1$
M&%4#@ #L*?1169H%%%% !1110 4444 >7_'_ /Y)W;_]A&/_ - DKYOKZ1^/
MW_).[?\ [",?_H$E?-U:PV,I;A1115DGT7^SW_R(5_\ ]A-__145>JUY5^SW
M_P B#??]A-__ $5%7JM8RW-H[!1114C"BBB@ HHHH **** "BBB@ HHHH ^?
M_P!HC_D9=(_Z]&_]#->/U[!^T1_R,ND?]>C?^AFO'ZVCL92W"BBBJ)/KCX:?
M\DST'_KT6NHKE_AK_P DTT'_ *]%KJ*P>YLM@HHHI#"BBB@ HHHH **** "B
MBB@ HHHH ^4OBY_R5;6_^ND?_HI*XRNS^+G_ "5;6_\ KI'_ .BDKC*W6QB]
MPJUI?_(7L_\ KNG_ *$*JU:TO_D+V?\ UW3_ -"%,1]K4445SFX4444 %%%%
M !1110 5D>)_#&F^+=%DTS5XM\;<HZ\/$W9E/8__ *C6O10!\B^-O VI^"-6
M-M?KYMM(2;>[1?DE']&]1_,<US-?:>K:18:[IDNGZM;)<VLHPT;C]0>H(]1S
M7SKX_P#@]J?A=I;_ $82:AI(RQ(&98!_M =1_M#\<5K&5]S-QL>;44459 5T
MGAOQ]XD\*D+I&I2+ .MM+^\B/_ 3T^HP:YNB@#W/1/VAXRJIXCT9E;O-8OD'
M_@#'C_OHUW&F_%[P5J0&-86V<_P74;1X_$C;^M?*E%1RHKF9]FV_B;0KQ0UI
MK6GS@]X[I&_D:LG5-/ R;ZV /_39?\:^*:*7(/G/LZ;Q%HENI,^L:?$!U+W2
M#'YFL34?BEX+TP'SM?MIF[+:YFS^* BODRBGR(.<]]UK]H73H=R:#I$]TW02
MW3B)?K@9)'Y5YGXB^*?BOQ(KQ7.HFUMGX-O9CRE(]"?O$>Q)KCJ*:BD3S-A1
M115""BBNQ\$?#76O&MPLD$9M--#8DO95^7W"#^(_3CU(HV&8.@>']2\3:Q%I
MNCVYGN).O947NS'L!ZU]0^ O &G^!M)\J#$]_,!]INRO+G^Z/11Z?B:T/"OA
M#2/!VEBRT>WVYP99WYDF/JQ_IT':MRL92N:*-@HHHJ2@HHHH P?'7_)/?$'_
M &#;C_T6U?'M?87CK_DGOB#_ +!MQ_Z+:OCVM8;&<PHHHJR K1T#0[SQ'KMK
MI6FION+E]HST4=V/L!DGZ5G5]*?!KP%_PC6A?VQJ46W4]00$*PY@BZA?8G@G
M\!VI2=D-*[.W\->'K/PMX>M=)TY?W4"_,Y',C'[S'W)_PK5HHK V"BBB@ HH
MHH **** "BBB@"*YMH;RUEMKJ-98)D*21L,AE(P0?PKY.^(?@R;P5XIELL,U
ME-F6TE/\29Z$^HZ'\#WKZVKE?B'X,A\:^%I;+"K>PYEM)3_#)CH3Z'H?P/:J
MB[,F2NCY)HJ6YMIK*[EMKJ)HIX7,<D;C!5@<$&HJV,@KMOA=XX;P9XH4W+G^
MS+PB*[7^[_=D^JY_(FN)HHW'L?;Z.LD:O&P=& *LIR"/6EKR#X'>._[1T_\
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M?P'>OI2L[0-#L_#FA6NE::FRWMDVC/5CW8^Y.2:T:RD[LU2L@HHHJ1A1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !65>^%M
MU$DW^B:?<,?XI;5&/YD9HHH P[KX3^"+O/F:!"A_Z8R21_\ H+"J!^"7@@MD
M:?.!Z"ZDQ_.BBJNQ61<M_A#X&MB"NA(Y]99Y7_0MBMBS\%>&+ @VGA_38V'1
MOLJ%OS(S112NPLC:1%C0)&JHHX"J, 4ZBBD,**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
"_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
